Medications for concurrent mental disorders among people with opioid use disorder: estimating adverse effects and the causal effect on opioid agonist treatment outcomes.

阿片类药物使用障碍患者并发精神障碍的药物治疗：估计不良反应以及对阿片类激动剂治疗结果的因果影响。

• 批准号: 416766
• 负责人: Krebs Emmanuel
• 金额: $ 7.65万
• 依托单位: Simon Fraser University (Burnaby, B.C.)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-11-01 至 2022-11-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=416766&lang=en
• 关键词: Causal Inference; Concurrent Disorders; Health Administrative Data; Health Economics; Machine Learning; Mental Disorder; Mental Illness; Opioid Use Disorder

More than half of Canadians seeking addiction treatment also have a mental disorder. In British Columbia, the prevalence of concurrent mental disorders among people with an opioid use disorder is as high as 74%. Sustained retention in opioid agonist treat

超过一半的加拿大人寻求成瘾治疗也有精神障碍。在不列颠哥伦比亚省，阿片类药物使用障碍患者并发精神障碍的患病率高达74%。阿片类激动剂治疗中的持续潴留